Hypercholesterolemia is one of the main risk factors for coronary heart disease and significantly contributes to the high mortality associated with cardiovascular diseases. Statin therapy represents the gold standard in the reduction of low-density lipoprotein cholesterol concentration. Nevertheless,
many patients still cannot achieve the recommended target levels, due to
either inadequate effectiveness or intolerance of these drugs. Monoclonal
antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9)
have emerged as a promising option in lipid-lowering treatment. After confirmation of their efficacy and safety in clinical trials, evolocumab and alirocumab received approval from the US Food and Drug Administration (FDA)
and European Medicines Agency (EMA) for introduction into clinical practice.
In this review, we present a history of the development and mechanisms
of action, as well as the results of the most important studies concerning
PCSK9 inhibitors
